Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1987 2
1988 4
1990 1
1991 1
1992 2
1993 2
1994 4
1995 5
1996 1
1997 5
1998 1
1999 5
2000 11
2001 14
2002 17
2003 27
2004 21
2005 28
2006 35
2007 32
2008 42
2009 40
2010 44
2011 59
2012 46
2013 61
2014 72
2015 111
2016 130
2017 122
2018 128
2019 98
2020 124
2021 151
2022 154
2023 161
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

1,566 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for christophe versus
Search for Christophe Verjus instead (3 results)
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Costa OS, et al. Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8. Crit Care. 2022. PMID: 35710578 Free PMC article.
We evaluated the effectiveness and safety of andexanet alfa versus 4F-PCC for management of apixaban- or rivaroxaban-associated intracranial hemorrhage (ICH). ...Andexanet alfa was associated with greater odds of achieving hemostatic effectiveness (85.8% vs. 68.1%; OR 2.73 …
We evaluated the effectiveness and safety of andexanet alfa versus 4F-PCC for management of apixaban- or rivaroxaban-associated intra …
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Larkin J, et al. J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3. J Clin Oncol. 2018. PMID: 28671856 Free PMC article. Clinical Trial.
Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 1 …
Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free …
Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial.
Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, Glass A, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Fattori R, Ince H; INSTEAD-XL trial. Nienaber CA, et al. Circ Cardiovasc Interv. 2013 Aug;6(4):407-16. doi: 10.1161/CIRCINTERVENTIONS.113.000463. Epub 2013 Aug 6. Circ Cardiovasc Interv. 2013. PMID: 23922146 Free article. Clinical Trial.
Cox regression was used to compare outcomes between groups; all analyses are based on intention to treat. The risk of all-cause mortality (11.1% versus 19.3%; P=0.13), aorta-specific mortality (6.9% versus 19.3%; P=0.04), and progression (27.0% versus 46.1%; …
Cox regression was used to compare outcomes between groups; all analyses are based on intention to treat. The risk of all-cause mortality (1 …
Hypertrichosis.
Saleh D, Yarrarapu SNS, Cook C. Saleh D, et al. 2023 Aug 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30521275 Free Books & Documents.
These are based on the distribution (generalized vs. localized), the age of onset (congenital versus acquired), and the type of hair (vellus versus terminal). Forms of generalized hypertrichosis include, but are not limited to, congenital generalized hypertrichosis …
These are based on the distribution (generalized vs. localized), the age of onset (congenital versus acquired), and the type of hair …
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Stueven AK, et al. Int J Mol Sci. 2019 Jun 22;20(12):3049. doi: 10.3390/ijms20123049. Int J Mol Sci. 2019. PMID: 31234481 Free PMC article. Review.
Moreover, the combination of SSA with peptide receptor radionuclide therapy (PRRT) in small intestinal NETs has proven efficacy in the phase 3 neuroendocrine tumours therapy (NETTER 1) trial. PRRT is currently being tested for enteropancreatic NETs versus everolimus in the …
Moreover, the combination of SSA with peptide receptor radionuclide therapy (PRRT) in small intestinal NETs has proven efficacy in the phase …
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S, Visser M, Tersteegen A, Dietze-Torres J, Glunz J, Gerdes C, Laux V, Stampfuss J, Roehrig S. Heitmeier S, et al. J Thromb Haemost. 2022 Jun;20(6):1400-1411. doi: 10.1111/jth.15700. Epub 2022 Mar 25. J Thromb Haemost. 2022. PMID: 35289054 Free PMC article.
METHODS: The effects of asundexian on FXIa activity, selectivity versus other proteases, plasma thrombin generation, and clotting assays were evaluated. ...In the FeCl(2) -injury models, asundexian reduced thrombus weight versus control, and in the arterial model wh …
METHODS: The effects of asundexian on FXIa activity, selectivity versus other proteases, plasma thrombin generation, and clotting ass …
Clocking in to immunity.
Scheiermann C, Gibbs J, Ince L, Loudon A. Scheiermann C, et al. Nat Rev Immunol. 2018 Jul;18(7):423-437. doi: 10.1038/s41577-018-0008-4. Nat Rev Immunol. 2018. PMID: 29662121 Review.
Retroperitoneal Hematoma.
Mondie C, Maguire NJ, Rentea RM. Mondie C, et al. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32644354 Free Books & Documents.
The easiest way to dichotomize this diagnosis is to classify retroperitoneal hematoma as traumatic versus nontraumatic. The traumatic retroperitoneal hematoma heading can be further subdivided into penetrating versus blunt. ...
The easiest way to dichotomize this diagnosis is to classify retroperitoneal hematoma as traumatic versus nontraumatic. The traumatic …
1,566 results